<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00891592</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 02707</org_study_id>
    <nct_id>NCT00891592</nct_id>
  </id_info>
  <brief_title>Umbilical Cord Blood Transplant for Hematological Malignancies</brief_title>
  <acronym>UCB</acronym>
  <official_title>A Phase 1 Dose Escalation Study of Infusion of ex Vivo cd3/cd28 Costimulated Umbilical Cord Blood-derived t Cells in Adults Undergoing Transplantation for Advanced Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol will enroll subjects with advanced hematologic malignancies who do not have a&#xD;
      suitable related or unrelated donor to undergo a Stem Cell Transplant.&#xD;
&#xD;
      In this study, subjects will undergo a Stem Cell Transplant using Cord Blood. Part of the&#xD;
      cord blood will be used for the Stem Cell Transplant and part of the cord blood will be sent&#xD;
      to a laboratory in order to grow the T cells (from the cord blood) and increase the activity&#xD;
      of the cord blood T cells.&#xD;
&#xD;
      The purpose of this part of the study is to see if it is safe to give study subjects&#xD;
      activated T cells made from a small portion of their donor UCB unit immediately after the UCB&#xD;
      transplant. Activated T cells have been used safely in stem cell transplantation studies in&#xD;
      the past, but they have never been studied UCB transplantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main study intervention includes CD3/CD28 ex vivo costimulated T cells derived from a&#xD;
      thawed umbilical cord blood unit, co-infused following a myeloablative conditioning regimen.&#xD;
&#xD;
      Activated T cells are T cells that have been activated in the laboratory by exposure to 2&#xD;
      compounds or molecules called CD3 and CD28; when T cells are exposed to both of these&#xD;
      compounds at the same time, they become activated or &quot;stimulated&quot; and may be more effective&#xD;
      in fighting infections, cancer cells, and promoting the recovery of red cells, white cells,&#xD;
      and platelets after transplantation. At the Hospital of the University of Pennsylvania,&#xD;
      activated T cells are prepared at the Clinical Cell and Vaccine Production Facility, also&#xD;
      known as the CVPF.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicity (DLT) is defined as grade 4 acute GVHD within the first 90 days following infusion.</measure>
    <time_frame>90 Days post Transplant</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>CML</condition>
  <condition>AML</condition>
  <condition>MDS</condition>
  <condition>ALL</condition>
  <condition>NHL</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Hodgkin's Disease</condition>
  <arm_group>
    <arm_group_label>Dose Escalation Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with cord blood stored in more than one fraction will be enrolled into Dose Escalation Arm. Subjects will receive Cord Blood Stem Cell Transplant followed by expanded Cord Blood T cells on Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observation Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects with cord blood stored in one fraction will be enrolled into the Observation Arm. Subjects will receive Cord Blood Stem Cell Transplant on Day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ex Vivo CD3/CD28 costimulated Umbilical Cord Blood T cells</intervention_name>
    <description>Single infusion of Cord Blood Cells AND Single Infusion of ex vivo CD3/CD28 costimulated Umbilical Cord Blood T cells.&#xD;
Table 6: Dose escalation (Dose level CD3+ cell dose)&#xD;
1xE5 cells/kg&#xD;
2xE6 cells/kg&#xD;
3xE7 cells/kg&#xD;
4xE8 cells/kg</description>
    <arm_group_label>Dose Escalation Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observation Arm</intervention_name>
    <description>Single infusion of Cord Blood Cells</description>
    <arm_group_label>Observation Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria.&#xD;
&#xD;
          -  Relapsed or persistent advanced hematologic malignancy; incurable with standard&#xD;
             chemotherapy and eligible for allogeneic HSCT, including:&#xD;
&#xD;
          -  CHRONIC MYELOGENOUS LEUKEMIA (CML). Subjects in accelerated or blast phase or subjects&#xD;
             in chronic phase with inadequate response to Imatinib or intolerant to Imatinib.&#xD;
&#xD;
          -  ACUTE MYELOGENOUS LEUKEMIA (AML). Subject with high risk disease in first complete&#xD;
             remission (CR). High risk disease includes the following cytogenetic abnormalities:&#xD;
             monosomy 7, deletion 5, trisomy 8, inversion 3, t(3;3), t(6;9), or t(6;11). Subjects&#xD;
             with complex cytogenetic abnormalities (more than 3 chromosomal abnormalities).&#xD;
&#xD;
          -  ACUTE MYELOGENOUS LEUKEMIA (AML). Subjects with diagnosis of AML after receiving&#xD;
             chemotherapy, radiation therapy or biopsy showing myelodysplastic syndrome.&#xD;
&#xD;
          -  ACUTE MYELOGENOUS LEUKEMIA (AML). Subjects with persistent AML after 2 cycles of&#xD;
             standard induction chemotherapy.&#xD;
&#xD;
          -  ACUTE MYELOGENOUS LEUKEMIA (AML). Subjects in first complete remission.&#xD;
&#xD;
          -  MYELODYSPLASTIC SYNDROME (MDS). Subjects with intermediate or high risk disease based&#xD;
             upon International Prognostic Scoring System.&#xD;
&#xD;
          -  ACUTE LYMPHOBLASTIC LEUKEMIA (ALL). Subjects with Philadelphia Chromosome (have&#xD;
             t(9;22) cytogenetic abnormality) or molecular documentation for BCR-ABL translocation.&#xD;
&#xD;
          -  ACUTE LYMPHOBLASTIC LEUKEMIA (ALL). Subjects with primary refractory disease or&#xD;
             subjects in 1st complete remission.&#xD;
&#xD;
          -  NHL or HODKIN'S DISEASE. Subjects who relapse following autologous Stem Cell&#xD;
             Transplant.&#xD;
&#xD;
          -  INDOLENT NHL. Subjects with progressive disease following &gt; 2 regimens.&#xD;
&#xD;
          -  MULTIPLE MYELOMA. Subjects who relapse following following autologous Stem Cell&#xD;
             Transplant.&#xD;
&#xD;
          -  Adults age 21-50.&#xD;
&#xD;
          -  Expected survival 4 weeks.&#xD;
&#xD;
          -  Subjects with no suitable related or unrelated donor for Stem Cell Transplant.&#xD;
&#xD;
          -  Subject has suitable Umbilical Cord Blood (UCB) unit available.&#xD;
&#xD;
          -  Subject has: Ejection fraction &gt; 45%; DLCO.45% predicted; Creatinine &lt; 2; Total&#xD;
             bilirubin &lt; 2X normal; Transaminases &lt; 2X normal.&#xD;
&#xD;
          -  Subject is capable of giving informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject is pregnant or lactating.&#xD;
&#xD;
          -  Subject has an uncontrolled infection.&#xD;
&#xD;
          -  Subject has an active or untreated disease involving the central nervous system.&#xD;
&#xD;
          -  Subject has an active or uncontrolled medical condition that would preclude&#xD;
             participation in the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Porter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elizabeth Hexner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.penncancer.org/clinicaltrials.cfm</url>
    <description>Abramson Cancer Center Clinical Trials</description>
  </link>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>April 29, 2009</study_first_submitted>
  <study_first_submitted_qc>April 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2009</study_first_posted>
  <last_update_submitted>August 17, 2016</last_update_submitted>
  <last_update_submitted_qc>August 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>MDS</keyword>
  <keyword>ALL</keyword>
  <keyword>NHL</keyword>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Hodgkin's</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

